PERSEPHONE: are we ready to de-escalate adjuvant trastuzumab for HER2-positive breast cancer?
Authors:
Open Access
- 4 January 2019
- journal article
- editorial
- Published by Springer Nature in npj Breast Cancer
- Vol. 5 (1) , 1-4
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER studyAnnals of Oncology, 2018
- Progress in adjuvant systemic therapy for breast cancerNature Reviews Clinical Oncology, 2018
- Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast CancerJAMA Oncology, 2018
- Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer: ASCO Clinical Practice Guideline Focused UpdateJournal of Clinical Oncology, 2018
- PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.Journal of Clinical Oncology, 2018
- Challenges in the Design and Interpretation of Noninferiority TrialsNew England Journal of Medicine, 2017
- Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)Annals of Oncology, 2015
- 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialThe Lancet, 2013
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trialThe Lancet Oncology, 2013
- Adjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast CancerNew England Journal of Medicine, 2006